Enhance your ability to manage obesity in cardiovascular patients with up-to-date guidance on FDA-approved pharmacological interventions. Through a focused discussion on pathophysiology, medication impact, and ethical considerations, this course empowers you to make informed, patient-centered decisions in a rapidly evolving therapeutic landscape.
Learning Objectives
- Review the epidemiology and pathophysiology of obesity including the neurohormonal pathways that cause weight gain and prevent sustained weight loss.
- Discuss the pharmacology and indications for the FDA approved anti obesity medications (AOMs) including GLP1-RA’s, along with cardiac considerations of each.
- Review other common obesity-inducing medications specific to the CV patient and considerations for combating these effects.
- Discuss ethical considerations for prescribing AOM’s with the current environment surrounding these medications
CE certificate available upon successful completion of the post-test and program evaluation.
MSN, NP, FAHA, FPCNA
DNP, ARNP, FNP-BC, FPCNA
Chiadi Ndumele
MD, PhD
Sheila Allen
Accreditation:
PCNA is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030602.
